Isofagomine tartrate
Alternative Names: afegostat tartrate; AT 2101; HGT-3410; isofagomine-ERT combo therapy; Plicera; Plicera-ERT combo therapyLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Novo Nordisk; University of Maryland, Baltimore
- Developer Amicus Therapeutics
- Class Antihyperglycaemics; Imino pyranoses; Pharmacological chaperones; Piperidines; Small molecules
- Mechanism of Action Glucosylceramidase stimulants; Protein folding stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gaucher's disease type I
- Discontinued Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gaucher's disease type I(Combination therapy) in USA (PO, Capsule)
- 28 Feb 2012 Isofagomine tartrate is still in preclinical trials for Gaucher's disease (combination therapy) in US
- 31 Jan 2012 Discontinued - Phase-II for Gaucher's disease type I in Germany (PO)